It’s almost impossible to name a country where healthcare budgets are not stretched. Whilst the attention of media, governments and regulators is often focused on new and innovative medicines, some countries are looking to save money by reducing the spend on generic drugs. In this double-issue article, Pope Woodhead draws on case studies from Canada and Australia to highlight the potential for reducing such costs, with the benefit of redirecting monies to meet other health needs.

Read more ...

Setting up a new Market Access function can be challenging and that challenge is magnified if the concept of Market Access is very new for the organisation too. In this podcast, Moreno Perugini, the Head of Market Access in Nestle Health Science talks about his experience of starting the Market Access function eighteen months ago and shares some valuable ‘lessons learnt’.

Read more ...

While an increasing number of pharmaceutical organisations are becoming alive to the benefits of digital, there’s no one-size-fits-all approach to implementing and managing change. It sounds simple, but a useful place to start is by being honest and realistic about what can be achieved, by whom, and by when. As this new paper highlights, there are universally applicable lessons that can inform and help shape a best-practice approach to digital transformation.

Read more ...

Reviewing and challenging evidence-generation opportunities in drug development

Evidence is king . . . or should be, particularly in an industry where development costs are high, timescales long, and outcomes serious. Yet some drug development initiatives are still not supported by high-quality evidence, leading to the inefficient use of resources and higher costs for payers and patients. As this paper illustrates, there is clearly a growing need to supplement expert opinion and qualitative information with more evidence, not least the real-world variety captured via online and digital technologies.

Read more ...

Addressing the challenges of regulating the dynamic, diverse and smart world of mobile health apps

The evolution of mobile smartphones, devices and apps continues to influence how we communicate, work and live. Healthcare is no exception. The market for mobile health technologies and apps is estimated to be worth US$23‑billion and brings real and potential benefits to new areas and patient groups.

Read more ...

A strategy based on real collaboration is key to achieving long-term success for pharma – here’s the how and why

Sometimes the simplest-sounding things are the most difficult to achieve. After all, most of us collaborate with colleagues on a daily basis. Yet real, structured collaboration that drives long-lasting benefits is more elusive. Our latest paper explores this theme via a case study of pioneering cloud computing company, Salesforce.

Read more ...

More Articles ...

Receive Our Newsletter

Please fill out the form below to receive our newsletter. Alternatively email